Folate-targeted perfluorohexane nanoparticles carrying bismuth sulfide for use in US/CT dual-mode imaging and synergistic high-intensity focused ultrasound ablation of cervical cancer

Zhou, Di; Li, Chuanfei; He, Minyu; Ma, Ming; Li, Pan; Gong, Yuping; Ran, Haitao; Wang, Zhibiao; Wang, Zhigang; Zheng, Yuanyi; Sun, Yong

doi:10.1039/c6tb00261g

Cited by 38 publications

(28 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MNP component of MNP‐gold core/shell NPs core could act as the CAs for MR imaging. By rational integration of Bi 2 S 3 NPs with PFH liposome, the concurrent computed tomography (CT) imaging and US imaging were achieved by taking the specific features of the high atomic number (Z) of bismuth (Bi) element for CT imaging and phase‐changeable capability of PFH droplet for US imaging …”

Section: Nanoparticulate Cas For Responsive Us Imagingmentioning

confidence: 99%

Materials Chemistry of Nanoultrasonic Biomedicine

2016

Self Cite

View full text Add to dashboard Cite

As a special cross-disciplinary research frontier, nanoultrasonic biomedicine refers to the design and synthesis of nanomaterials to solve some critical issues of ultrasound (US)-based biomedicine. The concept of nanoultrasonic biomedicine can also overcome the drawbacks of traditional microbubbles and promote the generation of novel US-based contrast agents or synergistic agents for US theranostics. Here, we discuss the recent developments of material chemistry in advancing the nanoultrasonic biomedicine for diverse US-based bio-applications. We initially introduce the design principles of novel nanoplatforms for serving the nanoultrasonic biomedicine, from the viewpoint of synthetic material chemistry. Based on these principles and diverse US-based bio-application backgrounds, the representative proof-of-concept paradigms on this topic are clarified in detail, including nanodroplet vaporization for intelligent/responsive US imaging, multifunctional nano-contrast agents for US-based multi-modality imaging, activatable synergistic agents for US-based therapy, US-triggered on-demand drug releasing, US-enhanced gene transfection, US-based synergistic therapy on combating the cancer and potential toxicity issue of screening various nanosystems suitable for nanoultrasonic biomedicine. It is highly expected that this novel nanoultrasonic biomedicine and corresponding high performance in US imaging and therapy can significantly promote the generation of new sub-discipline of US-based biomedicine by rationally integrating material chemistry and theranostic nanomedicine with clinical US-based biomedicine.

show abstract

Section: Nanoparticulate Cas For Responsive Us Imagingmentioning

confidence: 99%

Materials Chemistry of Nanoultrasonic Biomedicine

2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Passive Tumor Targeting Via the Epr Effectmentioning

confidence: 99%

Bismuth‐Based Nanomaterials: Recent Advances in Tumor Targeting and Synergistic Cancer Therapy Techniques

Badrigilan

Choupani

Khanbabaei

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Despite all of the efforts in the field of cancer therapy, the heterogeneous properties of tumor cells induce an insufficient therapeutic outcome when treated with conventional monotherapies, necessitating a shift in cancer treatment from monotherapy to combination therapy for complete cancer treatment. Multifunctional bismuth (Bi)‐based nanomaterials (NMs) with therapeutic functions hold great promise for the fields of cancer diagnosis and therapy based on their low toxicity, X‐ray sensitive capabilities, high atomic number, near‐infrared driven semiconductor properties, and low cost. Herein, a comprehensive review of recent advances in various medicinal aspects of Bi‐based NMs is presented including: evaluation of in‐tumor site accumulation, tumor targeting, and therapeutic performance, as well as the characteristics, benefits, and shortcomings of Bi‐based NM‐mediated major monotherapies. In addition, the cooperative enhancement mechanisms between two or more of these monotherapies are described in detail to address common challenges in cancer therapy, such as multidrug resistance, hypoxia, and metastasis. Finally, this review opens new insights into the design of multimodal synergistic therapies for potential future clinical applications of Bi‐based NMs.

show abstract

“…Based on this opinion, Zhou et al. have used folate modified perfluorohexane (PFC) NPs to carry Bi 2 S 3 nanodots for targeted CT imaging of tumor . Meanwhile, Kinsella et al.…”

Section: Bi‐based Nms Used For Cancer Diagnosismentioning

confidence: 99%

“…have prepared FL and CT dual‐mode imaging NPs through coating fluorescent QDs and Bi 2 S 3 NPs with silica shell. Moreover, when Bi 2 S 3 NPs are embedded in US contrast agents, such as poly(lactic‐co‐glycolic acid) (PLGA) or PFC, they can be used for both US and CT imaging. MR and CT dual‐mode imaging agents can also be obtained through hybrid MR agents with Bi‐based NPs.…”

Section: Bi‐based Nms Used For Cancer Diagnosismentioning

confidence: 99%

“…have used folate modified perfluorohexane (PFC) NPs to carry Bi 2 S 3 nanodots for targeted CT imaging of tumor. [29] Meanwhile, Kinsella et al have labeled Bi 2 S 3 NPs with the nine amino acid cyclic peptide (LyP-1, CGNKRTRGC)t hat can targetto4T1 breast cells, and the achieved NPs can preferentiallya ccumulate into 4T1 tumors (8.4 AE 2.1 %i njected dose per gram of tissue) relative to unlabeled NPs (3.2 AE 1.7 %i njected dose per gram of tissue), enabling acquisition of high-fidelity CT images of tumor ( Figure 2C). [30] With the similart argeting strategy, Yu et al [31] have labeled Bi NPs with LyP-1 peptide, too.…”

Section: Ct Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Novel Bismuth‐Based Nanomaterials Used for Cancer Diagnosis and Therapy

Cheng

Zhang

2018

Chemistry A European J

View full text Add to dashboard Cite

Theranostic nanomaterials (NMs) have gained increasing attention for their simultaneous performance of diagnosis and therapy. Bi-based NMs hold great potential as theranostic platforms based on their X-ray sensitive capability, near-infrared driven semiconductor properties, and distinctive structures, which facilitate the computed tomography (CT) imaging, photoacoustic (PA) imaging, radiation therapy, and phototherapy. The sophisticated design in composition, structure, and surface fabrication of Bi-based NMs can endow these NMs with more modalities in cancer diagnosis and therapy. In this Minireview, we focus on the recent advances in Bi-based theranostic NMs. A series of unique structures and functions as well as the underlying property-activity relationship of Bi-based NMs are showcased to highlight their promising imaging and therapeutic performance. At the end, we propose some challenges for the design and preparation of Bi-based NMs to improve their cancer diagnostic and therapeutic performance.

show abstract

Folate-targeted perfluorohexane nanoparticles carrying bismuth sulfide for use in US/CT dual-mode imaging and synergistic high-intensity focused ultrasound ablation of cervical cancer

Abstract: The integration of multifunctional contrast agents with HIFU synergistic therapy could real-time guide, monitor, and assess cancer therapeutic procedures and effects.

Cited by 38 publications

References 67 publications

Materials Chemistry of Nanoultrasonic Biomedicine

Materials Chemistry of Nanoultrasonic Biomedicine

Bismuth‐Based Nanomaterials: Recent Advances in Tumor Targeting and Synergistic Cancer Therapy Techniques

Novel Bismuth‐Based Nanomaterials Used for Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About